DK1362052T3 - Inhibitorer af cruzipain og andre cysteinproteaser - Google Patents

Inhibitorer af cruzipain og andre cysteinproteaser

Info

Publication number
DK1362052T3
DK1362052T3 DK02732145T DK02732145T DK1362052T3 DK 1362052 T3 DK1362052 T3 DK 1362052T3 DK 02732145 T DK02732145 T DK 02732145T DK 02732145 T DK02732145 T DK 02732145T DK 1362052 T3 DK1362052 T3 DK 1362052T3
Authority
DK
Denmark
Prior art keywords
inhibitors
cruzipain
cysteine proteases
general formula
compounds
Prior art date
Application number
DK02732145T
Other languages
Danish (da)
English (en)
Inventor
Martin Quibell
Original Assignee
Amura Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0101179A external-priority patent/GB0101179D0/en
Application filed by Amura Therapeutics Ltd filed Critical Amura Therapeutics Ltd
Application granted granted Critical
Publication of DK1362052T3 publication Critical patent/DK1362052T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DK02732145T 2001-01-17 2002-01-17 Inhibitorer af cruzipain og andre cysteinproteaser DK1362052T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0101179A GB0101179D0 (en) 2001-01-17 2001-01-17 Biologically active compounds
US27535901P 2001-03-13 2001-03-13
PCT/GB2002/000184 WO2002057270A1 (en) 2001-01-17 2002-01-17 Inhibitors of cruzipain and other cysteine proteases

Publications (1)

Publication Number Publication Date
DK1362052T3 true DK1362052T3 (da) 2007-07-09

Family

ID=26245571

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02732145T DK1362052T3 (da) 2001-01-17 2002-01-17 Inhibitorer af cruzipain og andre cysteinproteaser

Country Status (20)

Country Link
US (2) US7425562B2 (cg-RX-API-DMAC7.html)
EP (1) EP1362052B1 (cg-RX-API-DMAC7.html)
JP (1) JP4608183B2 (cg-RX-API-DMAC7.html)
KR (1) KR100860067B1 (cg-RX-API-DMAC7.html)
CN (1) CN1269822C (cg-RX-API-DMAC7.html)
AT (1) ATE356130T1 (cg-RX-API-DMAC7.html)
AU (1) AU2002219397B2 (cg-RX-API-DMAC7.html)
BR (1) BR0206501A (cg-RX-API-DMAC7.html)
CA (1) CA2436462C (cg-RX-API-DMAC7.html)
CY (1) CY1106640T1 (cg-RX-API-DMAC7.html)
DE (1) DE60218633T2 (cg-RX-API-DMAC7.html)
DK (1) DK1362052T3 (cg-RX-API-DMAC7.html)
ES (1) ES2281516T3 (cg-RX-API-DMAC7.html)
IL (2) IL156774A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA03006224A (cg-RX-API-DMAC7.html)
NO (1) NO328208B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ526913A (cg-RX-API-DMAC7.html)
PT (1) PT1362052E (cg-RX-API-DMAC7.html)
RU (1) RU2329266C2 (cg-RX-API-DMAC7.html)
WO (1) WO2002057270A1 (cg-RX-API-DMAC7.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7030116B2 (en) 2000-12-22 2006-04-18 Aventis Pharmaceuticals Inc. Compounds and compositions as cathepsin inhibitors
WO2002051983A2 (en) 2000-12-22 2002-07-04 Axys Pharmaceuticals, Inc. Novel compounds and compositions as cathepsin inhibitors
MXPA04002282A (es) 2001-09-14 2005-03-07 Axis Pharmaceutical Inc Nuevos compuestos y preparaciones como inhibidores de la catepsina.
EP1446392A1 (en) 2001-11-14 2004-08-18 Aventis Pharmaceuticals, Inc. Oligopeptides and compositions containing them as cathepsin s inhibitors
CN100354276C (zh) * 2002-07-16 2007-12-12 阿姆拉医疗有限公司 生物活性化合物
US7399765B2 (en) * 2003-09-19 2008-07-15 Abbott Laboratories Substituted diazabicycloalkane derivatives
SE0400022D0 (sv) * 2004-01-08 2004-01-08 Medivir Ab New compounds
DE602005019971D1 (de) * 2004-01-08 2010-04-29 Medivir Ab Inhibitoren von cysteinprotease
JP2005350417A (ja) * 2004-06-11 2005-12-22 Dai Ichi Seiyaku Co Ltd 還元的エーテル化法を用いたピロリジン誘導体の製造法
PL1865940T3 (pl) * 2005-03-21 2013-06-28 Virobay Inc Alfa-ketoamidowe związki jako inhibitory proteaz cysteinowych
GB0513839D0 (en) * 2005-07-07 2005-08-10 Medivir Ab Cysteine protease inhibitors
GB0513840D0 (en) * 2005-07-07 2005-08-10 Medivir Ab Cysteine protease inhibitors
GB0614037D0 (en) * 2006-07-14 2006-08-23 Amura Therapeutics Ltd Compounds
GB0614044D0 (en) * 2006-07-14 2006-08-23 Amura Therapeutics Ltd Compounds
GB0614053D0 (en) * 2006-07-14 2006-08-23 Amura Therapeutics Ltd Compounds
GB0614052D0 (en) * 2006-07-14 2006-08-23 Amura Therapeutics Ltd Compounds
GB0614073D0 (en) 2006-07-14 2006-08-23 Amura Therapeutics Ltd Compounds
GB0614042D0 (en) 2006-07-14 2006-08-23 Amura Therapeutics Ltd Compounds
GB0614046D0 (en) 2006-07-14 2006-08-23 Amura Therapeutics Ltd Compounds
WO2008114054A1 (en) * 2007-03-19 2008-09-25 Medivir Ab Protease inhibitors
US7893067B2 (en) * 2007-06-27 2011-02-22 Medivir Ab Cysteine protease inhibitors
JP5587790B2 (ja) * 2008-01-09 2014-09-10 アミュラ セラピューティクス リミティド 化合物
GB0804702D0 (en) * 2008-03-13 2008-04-16 Amura Therapeutics Ltd Compounds
GB0804701D0 (en) 2008-03-13 2008-04-16 Amura Therapeutics Ltd Compounds
US9409880B2 (en) 2011-01-20 2016-08-09 The Regents Of The University Of Colorado, A Body Corporate Modulators of TLR3/dsRNA complex and uses thereof
CN106963760A (zh) * 2012-08-30 2017-07-21 国立大学法人东京大学 体内寄生虫防治剂在制备防治体内寄生虫的药物中的用途
CN106279188A (zh) * 2016-07-21 2017-01-04 青岛科技大学 一种多取代呋喃并[2,3‑b]吡咯衍生物的制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3652574A (en) * 1970-04-01 1972-03-28 Abbott Lab Certain 1 2 3 4 - tetrahydro-5h-pyrido (4 3-b)indoles and the corresponding 1 2 3 4-tetrahydro-9h-pyrido(3 4-b)indoles and derivatives thereof
DE3601226A1 (de) * 1986-01-17 1987-07-23 Bayer Ag Dihydropyridinlactole, verfahren zur herstellung und ihre verwendung in arzneimitteln
RU2137768C1 (ru) * 1993-12-15 1999-09-20 Мерк энд Ко, Инк. Ингибиторы hiv протеазы
DZ2285A1 (fr) 1996-08-08 2002-12-25 Smithkline Beecham Corp Inhibiteurs de protéase de la cystéine.
EP0923535A4 (en) 1996-08-28 2001-01-10 Smithkline Beecham Corp CYSTEINE PROTEASE INHIBITORS
ZA9711537B (en) 1996-12-23 1998-06-25 Athena Neurosciences Inc Eli L Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting ß-amyloid peptide release and/or its synthesis by use of such compounds.
AR013079A1 (es) * 1997-05-06 2000-12-13 Smithkline Beecham Corp Derivados sustituidos de tetrahidrofurano-3-onas, de tetrahidropirano-3- onas y tetrahidrotiofen-3-onas, un procedimiento para su preparacion unacomposicion farmaceutica de un medicamento util como inhibidores de proteasas e intermediarios
MA26618A1 (fr) 1998-04-09 2004-12-20 Smithkline Beecham Corp Composes et compositions pharmaceutiques pour le traitement du paludisme
CO5150165A1 (es) 1998-11-13 2002-04-29 Smithkline Beecham Plc Inhibidores de proteasa: tipo catepsina k
GB9911417D0 (en) * 1999-05-18 1999-07-14 Peptide Therapeutics Ltd Furanone derivatives as inhibitors of cathepsin s
IL155961A0 (en) 2000-11-17 2003-12-23 Medivir Uk Ltd Cysteine protease inhibitors
WO2002051983A2 (en) 2000-12-22 2002-07-04 Axys Pharmaceuticals, Inc. Novel compounds and compositions as cathepsin inhibitors

Also Published As

Publication number Publication date
CN1269822C (zh) 2006-08-16
KR20030075161A (ko) 2003-09-22
DE60218633T2 (de) 2008-02-21
CY1106640T1 (el) 2012-01-25
WO2002057270A1 (en) 2002-07-25
NO328208B1 (no) 2010-01-11
ES2281516T3 (es) 2007-10-01
US7425562B2 (en) 2008-09-16
DE60218633D1 (de) 2007-04-19
RU2329266C2 (ru) 2008-07-20
ATE356130T1 (de) 2007-03-15
BR0206501A (pt) 2004-01-13
CA2436462A1 (en) 2002-07-25
RU2003125270A (ru) 2005-02-20
KR100860067B1 (ko) 2008-09-24
EP1362052A1 (en) 2003-11-19
IL156774A (en) 2008-08-07
US20090247471A1 (en) 2009-10-01
EP1362052B1 (en) 2007-03-07
HK1060729A1 (en) 2004-08-20
PT1362052E (pt) 2007-04-30
JP4608183B2 (ja) 2011-01-05
AU2002219397B2 (en) 2008-02-14
NZ526913A (en) 2004-12-24
CN1486320A (zh) 2004-03-31
IL156774A0 (en) 2004-02-08
NO20033220D0 (no) 2003-07-16
MXPA03006224A (es) 2004-10-15
NO20033220L (no) 2003-09-17
CA2436462C (en) 2011-07-05
JP2004518674A (ja) 2004-06-24
US20040138250A1 (en) 2004-07-15

Similar Documents

Publication Publication Date Title
NO20033220D0 (no) Inhibitorer for cruzipain og andre cysteinproteaser
TR199901191T2 (xx) Benzamidoaldehitlerin sistein proteaz� inhibit�r� olarak kullan�m�.
ATE445400T1 (de) Hydantion-derivate als hemmer von matrix- metalloproteinasen
CY1105386T1 (el) Βενζοϋλοσουλφοναμιδια και σουλφονυλβενζαμιδινες για χρηση σαν παραγοντες κατα του ογκου
UY27972A1 (es) Derivados de hidantoína
ATE348616T1 (de) 2-hydroxy-6-phenylphenanthridine als pde-4-hemmer
ATE353217T1 (de) 3-hydroxy-6-phenylphenanthridine als pde-4 inhibitoren
SE0201976D0 (sv) Novel compounds
TR200100605T2 (tr) Arilpiperazinler ve bunların metaloproteinaz inhibe edici maddeler (MMP) olarak kullanımı
BR0111451A (pt) Inibidores de serina protease
DK1569929T3 (da) Forbindelser og fremgangsmåder til behandling eller forebyggelse af flavi-virusinfektioner
DK1654261T3 (da) Hepatitis C-inhibitorforbindelser
EA200301100A1 (ru) Новые фталазиноны
CY1106247T1 (el) Θειοφαινο- και θειαζολοσουλφοναμιδες ως αντινεοπλαστικοι παραγοντες
ATE275544T1 (de) Serinprotease-inhibitoren
CY1108446T1 (el) Μη νευροτοξικοι παραγοντες ενεργοποιησης πλασμινογονου για την αντιμετωπιση αποπληξιας
ATE303384T1 (de) 1-biaryl-1,8-naphthyridin-4-one als phosphodieseterase-inhibitoren
ATE355101T1 (de) Inhibitoren von serin proteasen
NO20043016L (no) 6-aminomorfinan-derivater, fremgangsmate for fremstilling og anvendelse derav
DE60310767D1 (de) PYRAZOL-3,4-d-PYRIMIDINDERIVATE UND IHRE VERWENDUNG BEI DER BEHANDLUNG VON H.PYLORI-INFEKTIONEN
DE60316984D1 (de) Benzoylsulfonamide als antitumor-mittel
DK1379508T3 (da) N-(aryl)-2arylethensulfonamider og terapeutiske anvendelser deraf
SE0003476D0 (sv) Compounds
ATE333457T1 (de) Zyklische gmp-spezifische phosphodiesteraseinhibitoren
PT1377574E (pt) 6-fenilbenzonaftiridinas